Description

Insulin Glargine Injection (Toujeo) is a recombinant human insulin analog designed for sustained glucose control studies in laboratory models. Each unit contains 1.5ml delivering 450 international units (IU) in a prefilled, pen-type injector, excluding needle.

Manufactured by Sanofi (Beijing) Pharmaceutical Co., Ltd., Toujeo is widely recognized in scientific circles for its ultra-long-acting insulin glargine formulation, enabling consistent basal insulin levels in experimental metabolic studies.

?? This product is not for human administration. For investigational or lab use only.

Product Parameters

Mechanism & Research Applications

Insulin Glargine is a recombinant analog of human insulin modified for delayed and prolonged absorption. Once injected, it forms microprecipitates in subcutaneous tissue, providing a steady basal insulin release.

It is commonly used in preclinical studies involving:

• Basal insulin replacement models

• Type 1 and type 2 diabetes simulations

• Insulin receptor sensitivity research

• Pharmacokinetic comparisons with rapid-acting or intermediate insulin analogs

Observed Research Outcomes

• Steady 24-hour insulin exposure in vivo

• Reduced fluctuations in fasting blood glucose

• Minimal peak insulin concentrations

• Suitable for animal models requiring long-term glycemic control

Safety & Handling

• For research use only – not intended for human or animal therapy

• Requires cold chain storage (2–8°C)

• Do not reuse pen injector once opened

• Use aseptic techniques when handling

Research Use Disclaimer

This product is supplied exclusively for research and investigational purposes. It is not intended for human or veterinary use and should be handled only by qualified professionals.